Logo image of BODI

BEACHBODY CO INC/THE (BODI) Stock Fundamental Analysis

NYSE:BODI - New York Stock Exchange, Inc. - US0734633094 - Common Stock - Currency: USD

4.35  -0.2 (-4.4%)

Fundamental Rating

2

Overall BODI gets a fundamental rating of 2 out of 10. We evaluated BODI against 72 industry peers in the Diversified Consumer Services industry. BODI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BODI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BODI has reported negative net income.
BODI had a negative operating cash flow in the past year.
In the past 5 years BODI always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: BODI reported negative operating cash flow in multiple years.
BODI Yearly Net Income VS EBIT VS OCF VS FCFBODI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

BODI has a worse Return On Assets (-41.41%) than 80.56% of its industry peers.
BODI has a Return On Equity of -262.84%. This is in the lower half of the industry: BODI underperforms 75.00% of its industry peers.
Industry RankSector Rank
ROA -41.41%
ROE -262.84%
ROIC N/A
ROA(3y)-46.66%
ROA(5y)-36.36%
ROE(3y)-176.86%
ROE(5y)-122.28%
ROIC(3y)N/A
ROIC(5y)N/A
BODI Yearly ROA, ROE, ROICBODI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

BODI's Gross Margin of 69.42% is amongst the best of the industry. BODI outperforms 86.11% of its industry peers.
BODI's Gross Margin has been stable in the last couple of years.
BODI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y-1.01%
BODI Yearly Profit, Operating, Gross MarginsBODI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

BODI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BODI has more shares outstanding than it did 1 year ago.
BODI has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BODI is higher compared to a year ago.
BODI Yearly Shares OutstandingBODI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
BODI Yearly Total Debt VS Total AssetsBODI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

BODI has an Altman-Z score of -4.54. This is a bad value and indicates that BODI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.54, BODI is doing worse than 76.39% of the companies in the same industry.
There is no outstanding debt for BODI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.54
ROIC/WACCN/A
WACC11.37%
BODI Yearly LT Debt VS Equity VS FCFBODI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

BODI has a Current Ratio of 0.52. This is a bad value and indicates that BODI is not financially healthy enough and could expect problems in meeting its short term obligations.
BODI's Current ratio of 0.52 is on the low side compared to the rest of the industry. BODI is outperformed by 73.61% of its industry peers.
BODI has a Quick Ratio of 0.52. This is a bad value and indicates that BODI is not financially healthy enough and could expect problems in meeting its short term obligations.
BODI has a Quick ratio of 0.41. This is amonst the worse of the industry: BODI underperforms 81.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.41
BODI Yearly Current Assets VS Current LiabilitesBODI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

BODI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.06%, which is quite impressive.
BODI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.11%.
Measured over the past years, BODI shows a very negative growth in Revenue. The Revenue has been decreasing by -11.14% on average per year.
EPS 1Y (TTM)46.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.62%
Revenue 1Y (TTM)-26.11%
Revenue growth 3Y-21.74%
Revenue growth 5Y-11.14%
Sales Q2Q%-39.72%

3.2 Future

The Earnings Per Share is expected to grow by 24.47% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -25.18% on average over the next years. This is quite bad
EPS Next Y57.44%
EPS Next 2Y24.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-41.79%
Revenue Next 2Y-25.18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BODI Yearly Revenue VS EstimatesBODI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M
BODI Yearly EPS VS EstimatesBODI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BODI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BODI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BODI Price Earnings VS Forward Price EarningsBODI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BODI is valued cheaper than 97.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.03
BODI Per share dataBODI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

BODI's earnings are expected to grow with 24.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.47%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BODI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEACHBODY CO INC/THE

NYSE:BODI (7/31/2025, 4:15:01 PM)

4.35

-0.2 (-4.4%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners40.75%
Inst Owner ChangeN/A
Ins Owners5.21%
Ins Owner Change7.45%
Market Cap30.49M
Analysts80
Price Target10.54 (142.3%)
Short Float %6.09%
Short Ratio4.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.24%
Min EPS beat(2)-77.42%
Max EPS beat(2)42.94%
EPS beat(4)3
Avg EPS beat(4)9.88%
Min EPS beat(4)-77.42%
Max EPS beat(4)51.05%
EPS beat(8)4
Avg EPS beat(8)-4.53%
EPS beat(12)5
Avg EPS beat(12)-9.36%
EPS beat(16)8
Avg EPS beat(16)-7.94%
Revenue beat(2)2
Avg Revenue beat(2)7.92%
Min Revenue beat(2)5.31%
Max Revenue beat(2)10.54%
Revenue beat(4)2
Avg Revenue beat(4)2.63%
Min Revenue beat(4)-2.88%
Max Revenue beat(4)10.54%
Revenue beat(8)4
Avg Revenue beat(8)2.03%
Revenue beat(12)6
Avg Revenue beat(12)1.32%
Revenue beat(16)8
Avg Revenue beat(16)1.01%
PT rev (1m)0%
PT rev (3m)-2.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.2%
EPS NY rev (1m)0%
EPS NY rev (3m)16.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.08
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB N/A
EV/EBITDA 3.03
EPS(TTM)-8.36
EYN/A
EPS(NY)-4.3
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS52.94
BVpS3.43
TBVpS-7.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.41%
ROE -262.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.42%
FCFM N/A
ROA(3y)-46.66%
ROA(5y)-36.36%
ROE(3y)-176.86%
ROE(5y)-122.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y-1.01%
F-Score5
Asset Turnover2.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 8.26%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.41
Altman-Z -4.54
F-Score5
WACC11.37%
ROIC/WACCN/A
Cap/Depr(3y)15.58%
Cap/Depr(5y)44.94%
Cap/Sales(3y)2.05%
Cap/Sales(5y)3.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.62%
EPS Next Y57.44%
EPS Next 2Y24.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.11%
Revenue growth 3Y-21.74%
Revenue growth 5Y-11.14%
Sales Q2Q%-39.72%
Revenue Next Year-41.79%
Revenue Next 2Y-25.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y58.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year119.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.48%
OCF growth 3YN/A
OCF growth 5Y-42.85%